|
Lercanidipine
resources
DRUG INFO
Lercanidipine
Drug Name:
Lercanidipine
|
|
|
Indication: For the treatment of Hypertension and management of angina pectoris and Raynaud's syndrome
Pharmacology: Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism Of Action: By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Drug Category: Antihypertensive Agents; ATC:C08CA13
Brand Names/Synonyms: Lercanidipine; Lercanidipine [Inn]
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: methyl[2-(3,3-diphenylpropyl-methyl-amino)-1,1-dimethyl-ethyl]2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Chemical Formula: C36H41N3O6
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00193
CAS Registry Number: 100427-26-7
| | |
